TGTX

TG THERAPEUTICS INC

Healthcare | Mid Cap

$0.27

EPS Forecast

$255.6

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-12-31

TG Therapeutics (TGTX) lifts 2026 revenue forecast as BRIUMVI momentum and seven-year data echo into the future

TG Therapeutics, Inc. (TGTX) reports a solid third quarter in 2026 with total global revenue near $260 million, led by BRIUMVI (ublituximab-xiiy) U.S. net product revenue of about $233 million. The company also raised its full-year revenue guidance to approximately $1 billion, and tightened BR IUMVI guidance to roughly $915–$920 million in U.S. net product revenue. Management notes continued commercial momentum, and a host of late-stage data catalysts that could shape the stock’s trajectory in the near term and the longer arc of its pipeline.

For investors tracking EPS, earnings per share, and EPS consensus, the headline here is a revenue story baked into the model with ongoing expectations for margin expansion as BRIUMVI scales. The quarter’s results imply an earnings trajectory where any EPS upside will hinge on cost leverage and the pace of new launches—especially given a roughly $100 million share repurchase in the period signaling management’s confidence in value creation.

Financial snapshot

  • Total global revenue for Q3 2026: ≈ $259.9 million
  • BRIUMVI U.S. net product revenue (Q3 2026): ≈ $232.6 million (about 52% higher than year-ago quarter)
  • Q3 2026 revenue context: strength from BRIUMVI with ongoing IV-to-subcutaneous initiatives and pipeline opportunities
  • 2026 revenue guidance: raised to ≈ $1.0 billion
  • BRIUMVI U.S. net product revenue guidance (2026): ≈ $915–$920 million
  • Capital allocation: ~ $100 million of share repurchases during the quarter
  • Clinical catalysts: ENHANCE data supporting a simplified initiation regimen; Phase 3 subcutaneous BRIUMVI data; Phase 1 PK/bioavailability data

Clinical highlights and strategic data milestones

The press release emphasizes a suite of data milestones from MSToronto2026, including:

  • Phase 3 ENHANCE trial: Phase 3 results showed bioequivalence in exposure between the current two-infusion initiation and a consolidated single 600 mg initiation infusion. Infusion-related reactions were comparable, with no Grade 3+ events observed, supporting a potential simplified initiation schedule.
  • Phase 1 Subcutaneous BRIUMVI: Positive data demonstrated mean bioavailability greater than 60% relative to IV administration, bolstering the case for quarterly subcutaneous dosing and a more convenient treatment pathway.
  • Seven-Year Follow-up from ULTIMATE I & II: BRIUMVI demonstrated sustained efficacy with an annualized relapse rate (ARR) of 0.018 in year seven; 88.3% of continuously treated patients remained free from 24-week confirmed disability progression. Discontinuation or switching from competing regimens appeared to carry lower long-term benefit.

Taken together, the data underpin management’s belief that BRIUMVI can move from a compelling IV infusion to a more patient-friendly subcutaneous approach, potentially supporting a broader addressable market and higher patient adherence. That dynamic matters for revenue forecast accuracy and the company’s ability to translate clinical gains into durable EPS in the medium term.

Strategy, catalysts, and sector read-through

Management frames a succession of catalysts over the next 18–24 months, including pivotal Phase 3 subcutaneous BRIUMVI results around year-end 2026 to early 2027, a potential mid-2027 simplified IV initiation rollout, and a potential subcutaneous BRIUMVI launch in 2028. If these milestones hit, the earnings narrative for TGTX could shift from a single-product story to a broader franchise story, with investors weighing the optionality of subcutaneous administration against the costs and logistical realities of commercialization.

The guidance lift signals confidence, but the stock market will test that optimism against the company’s ability to sustain revenue growth, maintain margins, and execute on a multi-year subcutaneous program. For peers in the sector, the message is clear: the combination of strong quarterly revenue, a rising full-year revenue forecast, and meaningful data readouts on a convenient administration route raises the bar for productivity and the time-to-value calculus in B-cell lymphoma/oncology portfolios.

Implications for investors and sector peers

The Q3 print puts TGTX on a clearer revenue trajectory, with a credible path to a ~$1B revenue year and a substantial portion of that tied to BRIUMVI’s performance. In terms of earnings narrative, this sets up closer attention to EPS and EPS consensus as the company scales, particularly if subcutaneous initiation reduces operating costs or accelerates uptake in newly diagnosed or previously treated patients.

For sector peers, the episode reinforces the value of a diversified administration strategy, the upside of robust real-world uptake, and the importance of transparent revenue guidance revisions. Expect competitors to scrutinize BRIUMVI’s subcutaneous pathway and related cost implications as a potential model for other antibody-based therapies in similar therapeutic areas.

Bottom line

TG Therapeutics’ Q3 2026 results showcase a company converting product momentum into a higher revenue forecast, underpinned by compelling seven-year data for BRIUMVI and a clear path to a more convenient subcutaneous regimen. The key dynamic to watch remains whether the revenue trajectory translates into durable EPS growth and whether the upcoming data readouts can sustain the market’s currently buoyant expectations for TGTX and its peers.

Ticker reaction, EPS trajectory, and the sequencing of earnings surprises will be critical as analysts recalibrate their models around the new revenue forecast and the anticipated cadence of catalysts from MSToronto2026 onward.